Skip to main content

Table 4 In-hospital mortality in patients with community acquired severe sepsis at Haukeland University Hospital in 2008

From: Aetiology, antimicrobial therapy and outcome of patients with community acquired severe sepsis: a prospective study in a Norwegian university hospital

  Alla Non-survivors Unadjusted models Fully adjusted modelb Final modelc
Characteristic n n (%) OR 95% CI P value OR 95% CI P value OR 95% CI P value
Gender       0.240       
 Male 117 33 (28.2) 1.00 Reference        
 Female 103 22 (21.4) 0.69 (0.37, 1.29)        
Age (years)       0.065    0.619    
 16-30 18 1 (5.6) 1.00 Reference   1.00 Reference     
 30-45 22 4 (18.2) 3.78 (0.38, 37.28)   0.99 (0.07, 14.18)     
 45-60 36 8 (22.2) 4.86 (0.56, 42.30)   2.27 (0.19, 26.64)     
 60-75 68 16 (23.5) 5.23 (0.65, 42.43)   2.88 (0.28, 29.54)     
 ≥75 76 26 (34.2) 8.84 (1.11, 70.18)   3.09 (0.28, 33.54)     
Comorbidity             
 None 23 1 (4.3) 0.12 (0.02, 0.92) 0.005       
 Hypertension 91 18 (19.8) 0.61 (0.32, 1.17) 0.130       
 Cardiovascular 107 35 (32.7) 2.26 (1.20, 4.24) 0.010 2.18 (0.85, 5.61) 0.101 3.29 (1.45, 7.48) 0.003
 Pulmonary 61 14 (23.0) 0.86 (0.43, 1.72) 0.662       
 Diabetes 38 9 (23.7) 0.92 (0.40, 2.08) 0.836       
 Malignancy 31 13 (41.9) 2.53 (1.15, 5.58) 0.025 5.97 (1.96, 18.19) 0.001 5.50 (1.92, 15.78) 0.001
 Dementia 17 6 (35.3) 1.71 (0.60, 4.88) 0.324       
 Psychiatric 51 9 (17.6) 0.57 (0.26, 1.27) 0.155       
 Substance abuse 31 6 (19.4) 0.69 (0.27, 1.77) 0.423       
 Otherd 74 27 (36.5) 2.42 (1.29, 4.53) 0.006 2.52 (1.11, 5.70) 0.025 2.43 (1.10, 5.35) 0.026
Correct suspected focus of infection       0.020    0.606    
 Yes 152 31 (20.4) 1.00 Reference   1.00 Reference     
 No 68 24 (35.3) 2.13 (1.13, 4.02)   0.79 (0.33, 1.91)     
Confirmed focus of infection       0.007    0.003    0.001
 Respiratory 115 25 (21.7) 1.00 Reference   1.00 Reference     
 Genitourinary 31 4 (12.9) 0.53 (0.17, 1.67)   0.41 (0.08, 2.21)   0.47 (0.09, 2.39)  
 Soft tissue 27 6 (22.2) 1.03 (0.38, 2.82)   2.04 (0.55, 7.60)   2.42 (0.68, 8.68)  
 Abdominal 26 12 (46.2) 3.09 (1.27, 7.51)   2.95 (0.87, 10.03)   3.54 (1.09, 11.43)  
 Endocarditis 12 7 (58.3) 5.04 (1.47, 17.25)   17.43 (2.74, 111.06)   18.94 (3.45, 104.06)  
 Bacteremia 5 0 (0.0) 0.00 (0.00, )   0.00 (0.00, )   0.00 (0.00, )  
 CNS 4 1 (25.0) 1.20 (0.12, 12.04)   9.22 (0.71, 118.97)   7.66 (0.63, 93.73)  
Microbiological samples       0.008    0.028    0.025
 Positive 129 24 (18.6) 1.00 Reference   1.00 Reference   1.00 Reference  
 Negative 83 26 (31.3) 2.00 (1.05, 3.79)   3.58 (1.34, 9.55)   3.34 (1.29, 8.63)  
 Not obtained 8 5 (62.5) 7.29 (1.63, 32.63)   2.91 (0.35, 24.09)   4.44 (0.60, 32.95)  
Empirical antimicrobial agents             
 Suspected focus of infection       0.433       
  Appropriate compliance 171 38 (22.2) 1.00 Reference        
  Inappropriate compliance 39 11 (28.2) 1.38 (0.63, 3.02)        
 Confirmed focus of infection       0.027    0.241    
  Appropriate 168 35 (21.0) 1.00 Reference   1.00 Reference     
  Inappropriate 52 19 (36.5) 2.17 (1.10, 4.27)   0.79 (0.33, 1.91)     
 Microbiological aetiologye       < 0.001       
  Adequate 106 12 (11.3) 1.00 Reference        
  Inadequate 23 12 (52.2) 8.55 (3.10, 23.58)        
 In-hospital initial dose administered       0.002    0.051    0.046
  <6 hours after admission 157 30 (19.1) 1.00 Reference   1.00 Reference   1.00 Reference  
  ≥6 hours after admission 54 22 (40.7) 2.91 (1.49, 5.71)   2.52 (1.00, 6.38)   2.48 (1.02, 6.02)  
 Pre-hospital administration       0.059    0.055    0.041
  No 205 48 (23.4) 1.00 Reference   1.00 Reference   1.00 Reference  
  Yes 15 7 (46.7) 2.86 (0.99, 8.30)   4.13 (0.99, 17.21)   4.20 (1.08, 16.39)  
  1. Abbreviations: OR: odds ratio; CI: confidence interval.
  2. an = 220.
  3. bIncludes all categories with P < 0.10 in the unadjusted analyses; n = 211; Hosmer-Lemeshow’s chi-square = 12.38, df = 8, P = 0.135.
  4. cFrom backward stepwise selection at significance level 0.05; n = 211; Hosmer-Lemeshow’s chi-square = 3.18, df = 8, P = 0.923.
  5. dIncluding chronic kidney, liver and rheumatic diseases.
  6. eNot included in multivariate analysis due to a substantial number of not applicable cases (if included, significant in multivariate analysis).